Molecular Pharmacology Program

The David Scheinberg Lab

Research

David Scheinberg
David A. Scheinberg, MD, PhD
Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK

The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials and a vaccine to WT1 about to enter Phase III trials. Read full article in Science. A WT1 vaccine is also in late stage national trials (Blood, 2010).

We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013)

Research Projects

The David Scheinberg Lab

Publications

People

David Scheinberg

David A. Scheinberg, MD, PhD

Chair, Molecular Pharmacology Program, SKI; Director, Center for Experimental Therapeutics, MSK

  • Molecular Pharmacology Program Chair David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
  • MD, PhD, Johns Hopkins University School of Medicine
scheinbd@mskcc.org
Email Address
646-888-2190
Office Phone
View physician profile
Physician profile

Members

Michael Curcio

Senior Research Technician

Tao Dao

Senior Research Scientist

Tatyana Korontsvit

Senior Research Technician

Michael McDevitt

Member and Attending

David A. Scheinberg, MD, PhD
David A. Scheinberg

Member

Christopher Bourne

Graduate Student

Allison Clement

Research Technician

Megan Dacek

Graduate Student

Barbara de Mello, Sr. Research Technician
Barbara De Mello

Research Technician

Heather Jones

Graduate Student

Martin G. Klatt

Research Fellow

Sung Soo Mun

Senior Research Technician

Leila Peraro

Research Scholar

Pedro Silberman

Graduate Student

Lab Alumni
Emily C. Casey, BS
Emily C. Casey

Associate Medical Director at ApotheCom, San Francisco, CA

Aaron Chang

Graduate Student

Freddie Escorcia
Thomas J. Gardner, PhD
Thomas J. Gardner

Research Fellow

Ron Gejman
Ron Gejman

Graduate Student

William Maguire

Graduate Student

Prabodhika Mallikaratchy, PhD
Prabodhika Mallikaratchy

Visiting Scientist

Justin J. Mulvey

Graduate Student

Andrew Scott

Research Technician

Jonathan Seideman

Graduate Student

Nicholas Veomett

Graduate Student

Carlos Villa

Graduate Student

Sam Wong

Graduate Student

Victoriya Zakhaleva, Research Technician
Victoriya Zakhaleva

Research Technician

Bryan Aristega

Research Technician

Casey Jarvis

Research Technician

Melissa Mathias

Research Fellow

Lab Affilations

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

David A. Scheinberg discloses the following relationships and financial interests:

  • Actinium
    Intellectual Property Rights; Ownership / Equity Interests; Provision of Services
  • Arvinas, Inc
    Ownership / Equity Interests
  • Bridge Medicines
    Provision of Services (uncompensated)
  • ContraFect
    Ownership / Equity Interests
  • Ensysce Bioscience
    Ownership / Equity Interests
  • Eureka Therapeutics Inc
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Great Point Partners
    Ownership / Equity Interests; Provision of Services
  • Iovance Biotherapeutics, Inc.
    Ownership / Equity Interests
  • KLUS Pharma, Inc
    Provision of Services
  • Lantheus Medical Imaging, Inc.
    Ownership / Equity Interests
  • OncoPep, Inc.
    Provision of Services
  • Pfizer, Inc.
    Ownership / Equity Interests; Provision of Services
  • Progenics Pharmaceuticals, Inc.
    Provision of Services (uncompensated)
  • Sapience Therapeutics, Inc.
    Fiduciary Role/Position; Ownership / Equity Interests
  • Sellas Life Science Group
    Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures